HOOKIPA Pharma (HOOK) stock gains as Gilead Sciences agrees to acquire some of its antiviral assets for up to $10M. Read more ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

现在，吉利德决定将这2款候选疫苗完全掌控在自己手中。根据5月22日提交给美国证券交易委员会的一份文件， 吉利德将为此总共支付1000万美元，其中300万美元将在交易结束时支付，剩余的700万美元将分三阶段支付，对应技术转移计划的推进步骤。

HOOKIPA completed and delivered a regulatory support package for Gilead’s Phase 1 clinical trial of an investigational therapeutic vaccine for chronic hepatitis B using HOOKIPA’s arenaviral ...

Gilead holds 19.4% of HOOKIPA’s outstanding shares of common stock Equity investment is to advance the Gilead-partnered HIV therapeutic program through Phase 1; trial expected to commence in the ...

Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (Gilead), to be evaluated as a potential component of a curative regimen for human immunodeficiency ...

It would also have two Hookipa programmes partnered with Gilead Sciences, namely HB-500, an alternating, 2-vector arenaviral therapeutic vaccine that is being evaluated as part of a potential ...

("HOOKIPA") and Poolbeg Pharma plc ("Poolbeg ... The Combined Group would also have two partnered programmes with Gilead Sciences, Inc. ("Gilead"), offering the potential of significant ...